Alfonso de Dios

Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine

Lawrence M. Gelbert, Shufen Cai, Xi Lin et al. · Investigational New Drugs · 2014 · 565 citations · Full text

Medicine, Oncology, Pharmacology +17

The CDK4/6 Inhibitor Abemaciclib Induces a T Cell Inflamed Tumor Microenvironment and Enhances the Efficacy of PD-L1 Checkpoint Blockade

David Schaer, Richard P. Beckmann, Jack Dempsey et al. · Cell Reports · 2018 · 460 citations · Full text

Medicine, Immunology, Pharmacology +17

Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastoma Xenograft

Thomas J. Raub, Graham N. Wishart, Palaniappan Kulanthaivel et al. · Drug Metabolism and Disposition · 2015 · 281 citations

Medicine, Oncology, Pharmacology +17

Genomic Aberrations that Activate D-type Cyclins Are Associated with Enhanced Sensitivity to the CDK4 and CDK6 Inhibitor Abemaciclib

Xueqian Gong, Lacey M. Litchfield, Yue Webster et al. · Cancer Cell · 2017 · 236 citations · Full text

Life Sciences, Genetics, Molecular Biology +14

Preclinical characterization of abemaciclib in hormone receptor positive breast cancer

Raquel Torres-Guzmán, Bruna Calsina, Ana Hermoso et al. · Oncotarget · 2017 · 198 citations · Full text

Medicine, Oncology, Pharmacology +17